11 completed. 11 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 11 |
| Phase 2 | 4 | Completed 4 |
Follow Encephalomyelitis: new trials by email Literature Review of Encephalomyelitis trials Research Report on Encephalomyelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet - Long COVID-19 Syndrome, Chronic Fatigue Syndrome | Phase 3 | Completed | Cardresearch | 399 | 2023-10-18 | 2026-04-13 |
| Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome Prednisolone 20 mg/ 5 mg, Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12), Placebo for Vitamin B compound - Post-COVID-19 Syndrome | Phase 3 | Completed | Wuerzburg University Hospital | 321 | 2022-11-11 | 2025-04-01 |
| Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis Immunoglobulins, Intravenous (Privigen), Placebo - Encephalitis | Phase 3 | Completed | University of Oxford | 18 | 2016-01-01 | 2024-03-04 |
| B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Rituximab, Placebo - Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) | Phase 3 | Completed | Haukeland University Hospital | 151 | 2014-09-01 | 2021-05-11 |
| Cytokine Inhibition in Chronic Fatigue Syndrome Patients Anakinra, Placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 50 | 2014-06-01 | 2016-05-25 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
| Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients GCJBP Laennec Inj., Placebo - Chronic Fatigue Syndrome, Idiopathic Chronic Fatigue | Phase 3 | Completed | Ho Cheol Shin, M.D., Ph.D. | 78 | 2013-01-01 | 2013-09-26 |
| Drug Intervention in Chronic Fatigue Syndrome Rituximab, Saline (NaCl 0,9 %) (placebo) - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Haukeland University Hospital | 30 | 2008-06-01 | 2021-05-11 |
| Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Duloxetine 60 mg, QD - Fibromyalgia, HIV-1 Infection | Phase 3 | Completed | Germans Trias i Pujol Hospital | 10 | 2007-01-01 | 2019-12-04 |
| Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Duloxetine, Placebo - Fatigue Syndrome, Chronic | Phase 2 / Phase 3 | Completed | University of Cincinnati | 60 | 2006-09-01 | 2015-08-21 |
| The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Ampligen - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 3 | Completed | AIM ImmunoTech Inc. | 234 | 1998-12-01 | 2013-04-17 |
Fatigue Syndrome, Chronic (10) · Fatigue (4) · Fibromyalgia (2) · Pain (2) · Post-Acute COVID-19 Syndrome (2) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Encephalitis (1) · Meningoencephalitis (1)
Nervous System Diseases (11) · Neuroinflammatory Diseases (11) · Chronic Disease (10) · Disease Attributes (10) · Muscular Diseases (10) · Musculoskeletal Diseases (10) · Neuromuscular Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (5) · Infections (3) · COVID-19 (2) · Coronaviridae Infections (2) · Coronavirus Infections (2)
Sodium Chloride (3) · Duloxetine Hydrochloride (2) · Rituximab (2) · Ascorbic Acid (1) · Fluvoxamine (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Interleukin 1 Receptor Antagonist Protein (1) · NAD (1) · Phosphoserine (1) · Prednisolone (1) · Serine (1) · Sugars (1) · Vitamin B 12 (1) · coenzyme Q10 (1)
Haukeland University Hospital (2) · AIM ImmunoTech Inc. (1) · Cardresearch (1) · Germans Trias i Pujol Hospital (1) · Ho Cheol Shin, M.D., Ph.D. (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Radboud University Medical Center (1) · University of Cincinnati (1) · University of Oxford (1) · Wuerzburg University Hospital (1)
Norway (2) · Spain (2) · Brazil (1) · Germany (1) · Netherlands (1) · South Korea (1) · United Kingdom (1) · United States (1)
Olav Mella, MD, PhD (2) · Andrew J Pollard, FRCPCH, PhD (1) · David R Strayer, MD (1) · Gilmar Reis, MD,PhD. (1) · Ho Cheol Shin, M.D., Ph.d. (1) · Jos van der Meer, Prof, PhD, MD (1) · Jose Alegre-Martin, MD, PhD (1) · Lesley M Arnold, MD (1) · Negredo Eugenia, MD,PhD (1)
PMID 22039471, PMID 22431963, PMID 25386668, PMID 25660434, PMID 26212172, PMID 26438161, PMID 28265678, PMID 29284500, PMID 30934066, PMID 33119613, PMID 37945292, PMID 41911553, PMID 42832803
2014 (1)